annual meeting program - American Society of Clinical Oncology

9:30 AM - 12:30 PM
ORAL ABSTRACT SESSION
Leukemia, Myelodysplasia, and Transplantation
Location: E354b
CME credit: 3
Track(s): Leukemia, Myelodysplasia, and Transplantation
Monday, June 7, 2010
Jessica K. Altman, MD—Co-Chair
Northwestern University
William G. Blum, MD—Co-Chair
The Ohio State University
9:30 AM Dasatinib compared to imatinib (IM) in patients (pts) with newly diagnosed
chronic-phase chronic myelogenous leukemia in chronic phase (CML-CP):
Twelve-month efficacy and safety from the phase III DASISION study.
(Abstract #LBA6500)
H. Kantarjian, N. P. Shah, A. Hochhaus, J. E. Cortes, S. Shah, M. Ayala,
B. Moiraghi, M. Bradley-Garelik, C. Zhu, M. Baccarani
9:45 AM Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed
chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one
year. (Abstract #6501)
R. A. Larson, P. D. le Coutre, J. Reiffers, T. P. Hughes, G. Saglio, P. Edrich,
A. Hoenekopp, N. J. Gallagher, H. Kantarjian, A. Hochhaus
10:00 AM Safety and efficacy of bosutinib (SKI-606) in patients (pts) with chronic phase
(CP) chronic myeloid leukemia (CML) following resistance or intolerance to
imatinib (IM). (Abstract #6502)
J. E. Cortes, H. Kantarjian, T. Brümmendorf, H. J. Khoury, D. Kim, A. Turkina,
A. Volkert, J. Wang, S. Arkin, C. Gambacorti-Passerini
Discussion
10:15 AM Michael J. Mauro, MD (Abstracts #LBA6500–6502)
Oregon Health and Science University
Chronic Phase CML: Beyond Imatinib?
10:30 AM Time-dependent decision analysis: Stable disease in azacitidine (AZA)
treated patients (pts) with higher-risk MDS. (Abstract #6503)
S. Gore, P. Fenaux, V. Santini, J. M. Bennett, L. R. Silverman, J. F. Seymour,
E. Hellstrom-Lindberg, A. S. Swern, C. L. Beach, A. F. List
10:45 AM A randomized study of two dose levels of intravenous (IV) clofarabine (CLO)
in the treatment of patients (pts) with higher-risk myelodysplastic syndrome
(MDS). (Abstract #6504)
E. Jabbour, H. Kantarjian, G. Garcia-Manero, F. Ravandi Kashani, G. Borthakur,
Z. Estrov, V. Gandhi, A. Byrd, M. Kwari, S. Faderl
11:00 AM Improvement of leukemia-free survival (LFS) and reduction of relapse
incidence by allogeneic stem cell transplantation (SCT) in elderly patients
(pts) with AML irrespective of the FLT3-ITD and npm status except
npm�/flt3(ITD)-. (Abstract #6505)
D. Niederwieser, F. Schueler, U. Hegenbart, G. Maschmeyer, T. Fischer,
C. Junghanss, H. Wolf, H. G. Sayer, U. Kreibich, G. Doelken, East German Study
Group Hematology and Oncology OSHO
Discussion
11:15 AM Jeffrey E. Lancet, MD (Abstracts #6503–6505)
H. Lee Moffitt Cancer Center & Research Institute
High-risk MDS and AML in Elderly Patients: Are We Making Progress?
11:30 AM Long-term outcome after hyper-CVAD and imatinib (IM) for de novo or
minimally treated Philadelphia chromosome-positive acute lymphoblastic
leukemia (Ph-ALL). (Abstract #6506)
D. A. Thomas, S. M. O’Brien, S. Faderl, F. Ravandi Kashani, W. G. Wierda,
M. Andreeff, R. S. Garris, R. E. Champlin, J. E. Cortes, H. Kantarjian
345
MONDAY